BRISTOL MYERS SQUIBB CO (CELG-RI) Stock Price, Financials & Summary

Price chart

Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29

Key dataOct 29, 2026

Open$0.11

From 52W high−47.59%

Volume50.00

Market cap$223.74M

P/E (TTM)0.0x

P/S (TTM)0.0x

Div yield—

Key dataOct 29, 2026

Open

$0.11

From 52W high

−47.59%

Volume

50.00

Market cap

$223.74M

ValuationView details →

P/E (Fwd)

0.0x

EV/EBITDA

2.0x

P/E (TTM)

0.0x

RSI (14)

48.5

MomentumView details →

1D Return

+0.00%

YTD Return

+52.99%

SummaryUpdated Jun 1, 2026

Bristol-Myers Squibb Company (NYSE:BMY) is a major American pharmaceutical corporation founded in 1933 through the merger of Bristol-Myers Company and E.R. Squibb & Sons. Headquartered in Princeton, New Jersey, the company has evolved into one of the world's leading biopharmaceutical companies, focusing on the discovery, development, and commercialization of innovative medicines for serious diseases. Over its nine-decade history, Bristol-Myers Squibb has built a reputation as a pioneer in oncology, immunology, cardiovascular disease, and fibrosis treatments, with a particular emphasis on transforming patient outcomes through cutting-edge therapeutic approaches.

Ask drillr about BRISTOL MYERS SQUIBB CO →

ValuationView details →

P/E (Fwd)

0.0x

P/E (TTM)

0.0x

EV/EBITDA

2.0x

EV/Sales

0.7x

P/S (TTM)

0.0x

P/B (TTM)

0.0x

ProfitabilityView details →

Gross Margin

67.57%

Net Margin

18.87%

EBITDA Margin

34.74%

ROE (TTM)

41.59%

ROA (TTM)

10.59%

Asset Turnover

0.56x

GrowthView details →

Revenue YoY

+3.11%

EPS YoY

+83.06%

FCF YoY

−21.53%

Revenue CAGR 3Y

+1.45%

EPS CAGR 3Y

+5.32%

EBITDA YoY

+12.80%

MomentumView details →

1D Return

+0.00%

YTD Return

+52.99%

1Y Return

+261.84%

RSI (14)

48.5

vs 50D SMA

−5.36%

vs 200D SMA

−0.23%

Capital & dividendView details →

Debt/Equity

2.02x

Current Ratio

1.53x

Quick Ratio

1.38x

Div Yield

—

Div Rate

—

Div Growth 1Y

−80.97%

EarningsView details →

EPS (Actual)

$2.04

EPS Surprise

27.50%

Beats (12Q)

2/12

Next Q EPS Est

$1.59

Avg Surprise (4Q)

−11.71%

Rev Surprise

10.51%

Financials snapshotView financials →

Revenue (TTM)

49.19B

Net Income (TTM)

9.28B

Op. CF (TTM)

12.78B

Next earningsOct 29, 2026 →

Latest newsMore news →

BRISTOL MYERS SQUIBB CO reported quarterly earnings of $1.35 per share, compared with $1.63 per share a year earlier.3h ago

Similar companies

Modern Chinese Medicine Group Co., Ltd.01643.HK Beijing Biostar Pharms Co Ltd02563.HK Citius Oncology, Inc.CTOR TYK Medicines, Inc02410.HK Fangzhou Inc.06086.HK MIRA Pharmaceuticals, Inc.MIRA Find similar companies →

Latest newsMore news →

VEEVA SYSTEMS INC announced that executives from ASTRAZENECA PLC, BRISTOL MYERS SQUIBB CO, Grünenthal GmbH, NOVO NORDISK A S, Roche Holdings, Inc. and UCB SA are among those featured at Veeva Summit, which presents innovations in AI and data for an agent-based commercial model.2h ago BRISTOL MYERS SQUIBB CO reported quarterly earnings of $1.35 per share, compared with $1.63 per share a year earlier.3h ago BRISTOL MYERS SQUIBB CO raised the upper end of its 2026 revenue guidance to $50.25 billion from $50 billion.6h ago